Catalyst
Slingshot members are tracking this event:
Between second half 2017 and first half 2018, Intellia Therapeutics (NTLA) will start initial new drug application-based (IND) studies on Transtherytin Amyloidosis (ATTR), a gene-editing therapy using from CRISPR/Cas9 gene revision concept
- Source Link:
- http://seekingalpha.com/filing/3460363
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 18, 2018
Occurred Source:
http://ir.intelliatx.com/static-files/b15d1bdf-9109-4add-8bf5-c1d123f9425d
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ind Filing, Transtherytin Amyloidosis, Gene Replacement Therapy, Crispr-cas9
